Sixty-nine (69%) patients had hormone receptor-positive/HER2+ (HR+/HER2+) disease on primary site tumor, and the remaining 31 (31%) patients had HR-negative/HER2+ (HR−/HER2+) BC. The gene discussed is NR4A1; the disease is breast cancer.